Latest advances in early-stage breast cancer

Over the last decades, systemic therapy for patients with early-stage breast cancer has undergone remarkable enhancements, with the objectives and structures of neoadjuvant clinical trials continuously developing. In this podcast, we are joined by Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, Michael Gnant, MD, FACS, FEBS, Medical University of Vienna, Vienna, Austria, Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, Justin Balko, PharmD, PhD, Vanderbilt University Medical Center, Nashville, TN, as they discuss advances in early-stage HER2-positive, HR-positive and triple-negative breast cancer.